Phase I dose-escalation study of linsitinib (OSI-906) and erlotinib in patients with advanced solid tumors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoid Tumor
  • Lung Neoplasms
  • Neoplasm Recurrence, Local

abstract

  • The linsitinib/erlotinib combination was tolerable with preliminary evidence of activity, including durable responses in cases unlikely to respond to erlotinib monotherapy. Clin Cancer Res; 22(12); 2897-907. ©2016 AACR.

publication date

  • June 15, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5500904

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-15-2218

PubMed ID

  • 26831715

Additional Document Info

start page

  • 2897

end page

  • 907

volume

  • 22

number

  • 12